Background and Purpose: Tobacco smoke contains many classes of carcinogens and although nicotine is unable to initiate tumourigenesis in humans and rodents, it promotes tumour growth and metastasis in lung tumours by acting on neuronal nicotinic ACh receptors (nAChRs). The aim of this study was to identify molecularly, biochemically and pharmacologically which nAChR subtypes are expressed and functionally activated by nicotine in lung cancer cell lines. Experimental Approach: We used A549 and H1975 adenocarcinoma cell lines derived from lung tumours to test the in vitro effects of nicotine, and nAChR subtype-specific peptides and compounds. Key Results: The two adenocarcinoma cell lines express distinctive nAChR subtypes, and this affects their nicotine-induced proliferation. In A549 cells, nAChRs containing the alpha7 or alpha9 subunits not only regulate nicotine-induced cell proliferation but also the activation of the Akt and ERK pathways. Blocking these nAChRs by means of subtype-specific peptides, or silencing their expression by means of subunit-specific siRNAs, abolishes nicotine-induced proliferation and signalling. Moreover, we found that the alpha antagonist MG624 also acts on alpha9-alpha10 nAChRs, blocks the effects of nicotine on A549 cells and has dose-dependent cytotoxic activity. Conclusions and Implications: These results highlight the pathophysiological role of alpha7- and alpha9-containing receptors in promoting non-small cell lung carcinoma cell growth and intracellular signalling and provide a framework for the development of new drugs that specifically target the receptors expressed in lung tumours.

alpha9- and alpha7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line / V. Mucchietto, F.M. Fasoli, P. Susanna, M. Moretti, B. Roberta, A. Maroli, S. Di Lascio, C. Bolchi, M. Pallavicini, D. Cheryl, M. Michael, F. Clementi, G. Cecilia. - In: BRITISH JOURNAL OF PHARMACOLOGY. - ISSN 0007-1188. - 175(2018), pp. 1957-1972. [10.1111/bph.13954]

alpha9- and alpha7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line

V. Mucchietto;F.M. Fasoli;M. Moretti;A. Maroli;S. DI LASCIO;C. Bolchi;M. Pallavicini;F. Clementi;
2018

Abstract

Background and Purpose: Tobacco smoke contains many classes of carcinogens and although nicotine is unable to initiate tumourigenesis in humans and rodents, it promotes tumour growth and metastasis in lung tumours by acting on neuronal nicotinic ACh receptors (nAChRs). The aim of this study was to identify molecularly, biochemically and pharmacologically which nAChR subtypes are expressed and functionally activated by nicotine in lung cancer cell lines. Experimental Approach: We used A549 and H1975 adenocarcinoma cell lines derived from lung tumours to test the in vitro effects of nicotine, and nAChR subtype-specific peptides and compounds. Key Results: The two adenocarcinoma cell lines express distinctive nAChR subtypes, and this affects their nicotine-induced proliferation. In A549 cells, nAChRs containing the alpha7 or alpha9 subunits not only regulate nicotine-induced cell proliferation but also the activation of the Akt and ERK pathways. Blocking these nAChRs by means of subtype-specific peptides, or silencing their expression by means of subunit-specific siRNAs, abolishes nicotine-induced proliferation and signalling. Moreover, we found that the alpha antagonist MG624 also acts on alpha9-alpha10 nAChRs, blocks the effects of nicotine on A549 cells and has dose-dependent cytotoxic activity. Conclusions and Implications: These results highlight the pathophysiological role of alpha7- and alpha9-containing receptors in promoting non-small cell lung carcinoma cell growth and intracellular signalling and provide a framework for the development of new drugs that specifically target the receptors expressed in lung tumours.
Pharmacology
Settore BIO/14 - Farmacologia
2018
20-lug-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
2017 Mucchietto_et_al-British_Journal_of_Pharmacology.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.64 MB
Formato Adobe PDF
1.64 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/531000
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 67
  • ???jsp.display-item.citation.isi??? 59
social impact